Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: An EMPIRE trial sub-study

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1715-1723

  Goldstein, Barry J ^a   Weissman, Peter N ^b   Wooddell, Margaret J ^c   Waterhouse, Brian R ^c   Cobitz, Alexander R ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Cardiovascular biomarkers; Diabetes mellitus; Metformin; Rosiglitazone; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE B; HEMOGLOBIN A1C; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DYSPEPSIA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INJURY; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MATRIX METALLOPROTEINASE 9; METFORMIN; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749036035     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115720     Document Type: Article

References (51)

1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
2. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
5. Edelman SV. Type II diabetes mellitus. Adv Intern Med 1998;43:449-500
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
7. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21
8. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-41
9. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-9
10. Hanley AJ, Festa A, D'Agostino RB, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004;53:1773-81
11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
12. Zimmet P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc Med 2002;12:354-62
13. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65
14. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9
15. Thögersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7
16. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62
17. Festa A, Hanley AJ, Tracy RP, et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003;108:1822-30
18. Festa A, D'Agostino R, Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-7
19. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71
20. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-9
21. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72
22. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001;44:2210-9
23. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802
24. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51:3479-85
25. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004;21:568-76
26. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
27. Smith SA, Porter LE, Biswas N, et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin: insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004;89:6048-53
28. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
29. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34
30. Jones TA, Sautter M, Van Gaal LF, et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163-70
31. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27:1349-57
32. Honisett SY, Stojanovska L, Sudhir K, et al. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care 2003;26:3194-5
33. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52
34. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
35. Freed MI, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia 2000;43:A267
36. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005;21:2029-35
37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Guidelines for Good Clinical Practice. Available from http://www.ich.org/ [Last accessed 3 Mar 2006]
38. World Medical Association. World Medical Association Declaration of Helsinki. Available from http://www.wma.net/e/ethicsunit/helsinki.htm [Last accessed 3 Mar 2006]
39. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63
40. Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004;17:764-9
41. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004;21:810-7
42. Corti R, Hutter R, Badimon JJ, et al. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004;17:35-44
43. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990;82:II47-59
44. Ridker PM, Rifai N, Pfeffer MA, et al. Elevation of tumour necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53
45. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-8
46. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35
47. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003;107:636-42
48. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314-22
49. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726-35
50. Dormandy JA, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
51. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43